| pubmed-article:11214622 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11214622 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:11214622 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:11214622 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:11214622 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11214622 | pubmed:dateCreated | 2001-2-14 | lld:pubmed |
| pubmed-article:11214622 | pubmed:abstractText | The purposes of this study were to determine the efficacy of paclitaxel, using a dose of 200 mg/m2 intravenous continuous infusion over 24 hours every three weeks in the treatement of platinum-refractory epithelial ovarian cancer (EOC) and to evaluate the toxicities. Eligibility criteria included: histologically proven EOC, platinum resistance, measurable disease, Zubrod performance status grade 0-2, expected survival of > 3 months and adequate hematological function. Response was assessed at three-cycle intervals or earlier if required. Twenty-one patients were recruited in this study. The response rate was 52% (2 CR, 9 PR) with a median duration of response of six months. The median progression-free interval was eight months and the median survival was 12 months. Leukopenia was the predominant toxic effect. Eighty-six percent of patients required granulocyte-colony stimulation factor (G-CSF). All patients had alopecia grade 3. In conclusion, high-dose paclitaxel is active in platinum-refractory EOC with manageable toxicities. | lld:pubmed |
| pubmed-article:11214622 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11214622 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11214622 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11214622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11214622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11214622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11214622 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11214622 | pubmed:issn | 0392-2936 | lld:pubmed |
| pubmed-article:11214622 | pubmed:author | pubmed-author:WilailakSS | lld:pubmed |
| pubmed-article:11214622 | pubmed:author | pubmed-author:LinasmitaVV | lld:pubmed |
| pubmed-article:11214622 | pubmed:author | pubmed-author:TresukosolDD | lld:pubmed |
| pubmed-article:11214622 | pubmed:author | pubmed-author:Termrungruang... | lld:pubmed |
| pubmed-article:11214622 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11214622 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:11214622 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11214622 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11214622 | pubmed:pagination | 610-2 | lld:pubmed |
| pubmed-article:11214622 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:meshHeading | pubmed-meshheading:11214622... | lld:pubmed |
| pubmed-article:11214622 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11214622 | pubmed:articleTitle | Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. | lld:pubmed |
| pubmed-article:11214622 | pubmed:affiliation | Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. | lld:pubmed |
| pubmed-article:11214622 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11214622 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11214622 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11214622 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
